Infant Bacterial Therapeutics AB B
News & analysis
Times are shown in GMT+2, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improving feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.Infant Bacterial Therapeutics AB is a pharmaceutical company. The Company conducts research and development for developing a drug to treat the disease necrotizing enterocolitis.
Latest IBT B News